The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients
Metrics: PDF 446 views | HTML 1259 views | ?
Yong Mao1,*, Chengda Zou2,3,*, Fanyi Meng2, Jiehong Kong2, Weipeng Wang2 and Dong Hua1
1Department of Medical Oncology, Institute of Cancer, Affiliated Hospital of Jiangnan University and The Fourth People’s Hospital of Wuxi, Wuxi 214062, China
2Center for Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
3Department of Orthopedics, Children’s Hospital of Soochow University, Suzhou 215123, China
*These authors contributed equally to this work
Weipeng Wang, email: email@example.com
Dong Hua, email: firstname.lastname@example.org
Keywords: colon cancer; capecitabine; polymorphism; microRNA
Received: September 25, 2017 Accepted: December 01, 2017 Published: December 11, 2017
The single nucleotide polymorphisms (SNPs) in the microRNA precursor (pre-miRNA) may modulate the posttranscriptional regulation of gene expression and explain individual sensitivity to chemotherapy. Here we investigated the correlation between 23 SNPs in the pre-miRNA and the efficacy of capecitabine-based chemotherapy in 274 advanced colon cancer patients. Statistical analysis indicated that much more patients with rs744591 A/C(48.03%), C/C (53.45%) or C allele (49.73%) responded to the chemotherapy than those with the A/A genotype (33.71%). The response rates of rs745666 G/C heterozygous patients (35.25%) and C allele carriers (39.69%) were apparently less than that of the G/G homozygous patients (56.25%). Moreover, three SNPs rs2114358, rs35770269, and rs73239138 were significantly associated with the occurrence of side effects of chemotherapy. The patients with rs2114358 C allele (OR = 2.016) or rs35770269 T allele (OR = 2.299) were much more prone to endure adverse events. However, the incidence of side effect was lower in the patients carrying rs73239138 A allele than those with G/G genotype (OR = 0.500). Our findings demonstrate that genetic variations in pre-miRNA may influence the efficacy of capecitabine-based chemotherapy in advanced colon cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.